411 related articles for article (PubMed ID: 31601188)
41. JAK-STAT and JAK-PI3K-mTORC1 pathways regulate telomerase transcriptionally and posttranslationally in ATL cells.
Yamada O; Ozaki K; Akiyama M; Kawauchi K
Mol Cancer Ther; 2012 May; 11(5):1112-21. PubMed ID: 22402124
[TBL] [Abstract][Full Text] [Related]
42. PI-103 attenuates PI3K-AKT signaling and induces apoptosis in murineT-cell lymphoma.
Maurya AK; Vinayak M
Leuk Lymphoma; 2017 May; 58(5):1153-1161. PubMed ID: 27658642
[TBL] [Abstract][Full Text] [Related]
43. Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy.
Yu K; Toral-Barza L; Shi C; Zhang WG; Zask A
Cancer Biol Ther; 2008 Feb; 7(2):307-15. PubMed ID: 18059185
[TBL] [Abstract][Full Text] [Related]
44. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis.
Suzuki E; Umezawa K; Bonavida B
Oncogene; 2007 Sep; 26(42):6184-93. PubMed ID: 17420722
[TBL] [Abstract][Full Text] [Related]
45. The molecular mechanism of curcumol on inducing cell growth arrest and apoptosis in Jurkat cells, a model of CD4⁺ T cells.
Wang H; Wang Y; Jiang X; Wang Z; Zhong B; Fang Y
Int Immunopharmacol; 2014 Aug; 21(2):375-82. PubMed ID: 24877754
[TBL] [Abstract][Full Text] [Related]
46. Sensitizing B- and T- cell Lymphoma Cells to Paclitaxel/Abraxane-Induced Death by AS101 via Inhibition of the VLA-4-IL10-Survivin Axis.
Danoch H; Kalechman Y; Albeck M; Longo DL; Sredni B
Mol Cancer Res; 2015 Mar; 13(3):411-22. PubMed ID: 25351768
[TBL] [Abstract][Full Text] [Related]
47. Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K Axis.
Ma J; Wu K; Bai W; Cui X; Chen Y; Xie Y; Xie Y
EBioMedicine; 2017 Jun; 20():70-78. PubMed ID: 28529032
[TBL] [Abstract][Full Text] [Related]
48. WSTF promotes proliferation and invasion of lung cancer cells by inducing EMT via PI3K/Akt and IL-6/STAT3 signaling pathways.
Meng J; Zhang XT; Liu XL; Fan L; Li C; Sun Y; Liang XH; Wang JB; Mei QB; Zhang F; Zhang T
Cell Signal; 2016 Nov; 28(11):1673-82. PubMed ID: 27449264
[TBL] [Abstract][Full Text] [Related]
49. IL-2 activation of a PI3K-dependent STAT3 serine phosphorylation pathway in primary human T cells.
Fung MM; Rohwer F; McGuire KL
Cell Signal; 2003 Jun; 15(6):625-36. PubMed ID: 12681450
[TBL] [Abstract][Full Text] [Related]
50. Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date.
Mensah FA; Blaize JP; Bryan LJ
Onco Targets Ther; 2018; 11():4817-4827. PubMed ID: 30147333
[TBL] [Abstract][Full Text] [Related]
51. JAK2 inhibitor blocks the inflammation and growth of esophageal squamous cell carcinoma in vitro through the JAK/STAT3 pathway.
Fang J; Chu L; Li C; Chen Y; Hu F; Zhang X; Zhao H; Liu Z; Xu Q
Oncol Rep; 2015 Jan; 33(1):494-502. PubMed ID: 25405520
[TBL] [Abstract][Full Text] [Related]
52. On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors.
Morschhauser F; Machiels JP; Salles G; Rottey S; Rule SAJ; Cunningham D; Peyrade F; Fruchart C; Arkenau HT; Genvresse I; Liu L; Köchert K; Shen K; Kneip C; Peña CE; Grevel J; Zhang J; Cisternas G; Reschke S; Granvil C; Awada A
Mol Cancer Ther; 2020 Feb; 19(2):468-478. PubMed ID: 31619463
[TBL] [Abstract][Full Text] [Related]
53. Interleukin-6 reverses Adriamycin resistance in nasal NK/T-cell lymphoma via downregulation of ABCC4 and inactivation of the JAK2/STAT3/NF-κB/P65 pathway.
Gao M; Liu L; Zhang X; Li Z; Zhang M
Environ Toxicol Pharmacol; 2021 Jul; 85():103639. PubMed ID: 33771682
[TBL] [Abstract][Full Text] [Related]
54. Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation.
Grasso S; Tristante E; Saceda M; Carbonell P; Mayor-López L; Carballo-Santana M; Carrasco-García E; Rocamora-Reverte L; García-Morales P; Carballo F; Ferragut JA; Martínez-Lacaci I
Neoplasia; 2014 Oct; 16(10):845-60. PubMed ID: 25379021
[TBL] [Abstract][Full Text] [Related]
55. PAK1 mediates resistance to PI3K inhibition in lymphomas.
Walsh K; McKinney MS; Love C; Liu Q; Fan A; Patel A; Smith J; Beaven A; Jima DD; Dave SS
Clin Cancer Res; 2013 Mar; 19(5):1106-15. PubMed ID: 23300274
[TBL] [Abstract][Full Text] [Related]
56. GLI1 inhibitor GANT61 exhibits antitumor efficacy in T-cell lymphoma cells through down-regulation of p-STAT3 and SOCS3.
Geng L; Lu K; Li P; Li X; Zhou X; Li Y; Wang X
Oncotarget; 2017 Jul; 8(30):48701-48710. PubMed ID: 27275540
[TBL] [Abstract][Full Text] [Related]
57. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
58. Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
Dreyling M; Santoro A; Mollica L; Leppä S; Follows GA; Lenz G; Kim WS; Nagler A; Panayiotidis P; Demeter J; Özcan M; Kosinova M; Bouabdallah K; Morschhauser F; Stevens DA; Trevarthen D; Giurescu M; Cupit L; Liu L; Köchert K; Seidel H; Peña C; Yin S; Hiemeyer F; Garcia-Vargas J; Childs BH; Zinzani PL
J Clin Oncol; 2017 Dec; 35(35):3898-3905. PubMed ID: 28976790
[TBL] [Abstract][Full Text] [Related]
59. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
60. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.
Dreyling M; Morschhauser F; Bouabdallah K; Bron D; Cunningham D; Assouline SE; Verhoef G; Linton K; Thieblemont C; Vitolo U; Hiemeyer F; Giurescu M; Garcia-Vargas J; Gorbatchevsky I; Liu L; Koechert K; Peña C; Neves M; Childs BH; Zinzani PL
Ann Oncol; 2017 Sep; 28(9):2169-2178. PubMed ID: 28633365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
